Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],1.6,3898,DB00758,Clopidogrel
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],2.9,3899,DB00758,Clopidogrel
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],3.1,3900,DB00758,Clopidogrel
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],4.9,3901,DB00758,Clopidogrel
,10440419,T(max),Median T(max)(0.8-1.0 hour) and mean plasma t1/2 (7.2-7.6 hours) values were not significantly different between doses.,Pharmacokinetics of clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),h,0.8-1.0,3902,DB00758,Clopidogrel
,10440419,plasma t1/2,Median T(max)(0.8-1.0 hour) and mean plasma t1/2 (7.2-7.6 hours) values were not significantly different between doses.,Pharmacokinetics of clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),h,7.2-7.6,3903,DB00758,Clopidogrel
,10440419,C(trough),"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.8,3904,DB00758,Clopidogrel
,10440419,C(trough),"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.11,3905,DB00758,Clopidogrel
,10440419,at steady state,"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.8,3906,DB00758,Clopidogrel
,10440419,at steady state,"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.11,3907,DB00758,Clopidogrel
>,23542721,recoveries,Assay recoveries were high (>79%).,A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23542721/),%,79,4074,DB00758,Clopidogrel
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],2.29,6705,DB00758,Clopidogrel
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.99,6706,DB00758,Clopidogrel
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.58,6707,DB00758,Clopidogrel
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.36,6708,DB00758,Clopidogrel
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.24,6709,DB00758,Clopidogrel
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.01,6710,DB00758,Clopidogrel
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.13,6711,DB00758,Clopidogrel
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.1,6712,DB00758,Clopidogrel
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.84,6713,DB00758,Clopidogrel
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.62,6714,DB00758,Clopidogrel
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.46,6715,DB00758,Clopidogrel
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity at the start and end of PCI was 1.27 +/- 0.41 and 1.07 +/- 0.42, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.27,6716,DB00758,Clopidogrel
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity at the start and end of PCI was 1.27 +/- 0.41 and 1.07 +/- 0.42, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.07,6717,DB00758,Clopidogrel
,31039046,IC50,Alcohol significantly inhibited the hydrolysis of clopidogrel (IC50 161 mM) and 2-oxo-clopidogrel (IC50 6 mM).,Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039046/),mM,161,8457,DB00758,Clopidogrel
,31039046,IC50,Alcohol significantly inhibited the hydrolysis of clopidogrel (IC50 161 mM) and 2-oxo-clopidogrel (IC50 6 mM).,Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039046/),mM,6,8458,DB00758,Clopidogrel
,26839733,flow rate,Chromatographic separation was performed on an BDS Hypersil C18 column (250 × 4.6 mm; 5 μm) via gradient elution with mobile phase consisting of 10 mM phosphoric acid (sodium) buffer solution (pH = 2.6 adjusted with 85% orthophosphoric acid) : acetonitrile : methanol with flow rate of 1 mL·min(-1).,"Development and Validation of an HPLC Method for Simultaneous Quantification of Clopidogrel Bisulfate, Its Carboxylic Acid Metabolite, and Atorvastatin in Human Plasma: Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839733/),[ml] / [min],1,8719,DB00758,Clopidogrel
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],15.8,10569,DB00758,Clopidogrel
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],0.113,10570,DB00758,Clopidogrel
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],454,10571,DB00758,Clopidogrel
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],23.3,10572,DB00758,Clopidogrel
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,25,10573,DB00758,Clopidogrel
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,7,10574,DB00758,Clopidogrel
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,10,10575,DB00758,Clopidogrel
,17141580,flow rate,Analysis was performed using a C8 column (temperature controlled to 50 degrees C) by gradient elution at a flow rate of 0.9 mL min(-1) over a 3 min run time.,The validation of a bioanalytical method for the determination of clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141580/),[ml] / [min],0.9,11937,DB00758,Clopidogrel
,17141580,Retention times,"Retention times of 1.61 and 1.59 min were observed for clopidogrel and 2H3-clopidogrel (I.S.), respectively.",The validation of a bioanalytical method for the determination of clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141580/),min,1.61,11938,DB00758,Clopidogrel
,17141580,Retention times,"Retention times of 1.61 and 1.59 min were observed for clopidogrel and 2H3-clopidogrel (I.S.), respectively.",The validation of a bioanalytical method for the determination of clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141580/),min,1.59,11939,DB00758,Clopidogrel
,33510930,recoveries,Mean recoveries of apremilast in beagle dogs plasma ranged from 87.4% to 97.4%.,Quantitation of Apremilast in Beagle Dogs Plasma by UPLC-MS-MS and Its Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33510930/),%,87.4,13107,DB00758,Clopidogrel
,33510930,recoveries,Mean recoveries of apremilast in beagle dogs plasma ranged from 87.4% to 97.4%.,Quantitation of Apremilast in Beagle Dogs Plasma by UPLC-MS-MS and Its Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33510930/),%,97.4,13108,DB00758,Clopidogrel
,33510930,t1/2Z,The mean t1/2Z was 5.41 h for 30 mg·day-1 for beagle dogs after oral administration.,Quantitation of Apremilast in Beagle Dogs Plasma by UPLC-MS-MS and Its Application to Pharmacokinetic Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33510930/),h,5.41,13109,DB00758,Clopidogrel
,33510930,AUC0-t,The AUC0-t increased linearly from 3.51 to 1802.13 μg L-1 ∗h after administration of single doses.,Quantitation of Apremilast in Beagle Dogs Plasma by UPLC-MS-MS and Its Application to Pharmacokinetic Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33510930/),[μg·∗h] / [l],3.51,13110,DB00758,Clopidogrel
,33510930,AUC0-t,The AUC0-t increased linearly from 3.51 to 1802.13 μg L-1 ∗h after administration of single doses.,Quantitation of Apremilast in Beagle Dogs Plasma by UPLC-MS-MS and Its Application to Pharmacokinetic Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33510930/),[μg·∗h] / [l],1802.13,13111,DB00758,Clopidogrel
,30414387,half maximal inhibition,"On average, half maximal inhibition was reached at ticagrelor concentrations of 116 (RSE: 5.3%) nmol l-1 .",Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30414387/),%,116,13270,DB00758,Clopidogrel
,19634511,AUC(0-tlast),"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[h·pg] / [ml],"3,656.01",13350,DB00758,Clopidogrel
,19634511,AUC(0-tlast),"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[h·pg] / [ml],3771.51,13351,DB00758,Clopidogrel
,19634511,Cmax,"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[pg] / [ml],1970.22,13352,DB00758,Clopidogrel
,19634511,Cmax,"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[pg] / [ml],1756.52,13353,DB00758,Clopidogrel
,19634511,tmax,The mean tmax was 1.16 h for the test and 1.13 h for the reference formulation.,Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),h,1.16,13354,DB00758,Clopidogrel
,19634511,tmax,The mean tmax was 1.16 h for the test and 1.13 h for the reference formulation.,Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),h,1.13,13355,DB00758,Clopidogrel
,26695516,dose-adjusted concentrations,"Due to differences in the maintenance doses, we have calculated the dose-adjusted concentrations of clopidogrel (0.2 ng/ml/mg (0.1-0.4)) and 2-oxo-clopidogrel (2.1 ng/ml/mg (0.5-4.6)).",P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26695516/),[ng] / [mg·ml],0.2,14616,DB00758,Clopidogrel
,26695516,dose-adjusted concentrations,"Due to differences in the maintenance doses, we have calculated the dose-adjusted concentrations of clopidogrel (0.2 ng/ml/mg (0.1-0.4)) and 2-oxo-clopidogrel (2.1 ng/ml/mg (0.5-4.6)).",P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26695516/),[ng] / [mg·ml],2.1,14617,DB00758,Clopidogrel
better,9892073,extraction efficiency,The extraction efficiency was better than 48% over the range studied; for the internal standard it averaged 51% at 50 ng/ml.,Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892073/),%,48,16348,DB00758,Clopidogrel
,9892073,extraction efficiency,The extraction efficiency was better than 48% over the range studied; for the internal standard it averaged 51% at 50 ng/ml.,Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892073/),%,51,16349,DB00758,Clopidogrel
,24710841,AUC,"Similarly, PMs needed 300 mg daily to achieve active metabolite concentrations that were similar to EMs on 75 mg (AUC 37.7 and 33.5 ng h/mL, respectively).",Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710841/),[h·ng] / [ml],37.7,18438,DB00758,Clopidogrel
,24710841,AUC,"Similarly, PMs needed 300 mg daily to achieve active metabolite concentrations that were similar to EMs on 75 mg (AUC 37.7 and 33.5 ng h/mL, respectively).",Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710841/),[h·ng] / [ml],33.5,18439,DB00758,Clopidogrel
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,1.68,19503,DB00758,Clopidogrel
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,1.38,19504,DB00758,Clopidogrel
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,4.78,19505,DB00758,Clopidogrel
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,4.80,19506,DB00758,Clopidogrel
,23385314,K(i),Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 µM) and CYP2C19 (K(i) = 21.31 µM); and a weak inhibitor of CYP3A (K(i) = 40.33 µM).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,19.46,19507,DB00758,Clopidogrel
,23385314,K(i),Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 µM) and CYP2C19 (K(i) = 21.31 µM); and a weak inhibitor of CYP3A (K(i) = 40.33 µM).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,21.31,19508,DB00758,Clopidogrel
,23385314,K(i),Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 µM) and CYP2C19 (K(i) = 21.31 µM); and a weak inhibitor of CYP3A (K(i) = 40.33 µM).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,40.33,19509,DB00758,Clopidogrel
,10440421,AUC ratio,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.021,21263,DB00758,Clopidogrel
,10440421,AUC ratio,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.001,21264,DB00758,Clopidogrel
,10440421,t 1/2 ratios,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.019,21265,DB00758,Clopidogrel
,10440421,t 1/2 ratios,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.027,21266,DB00758,Clopidogrel
,25064036,IC50,SAR216471 blocks the binding of 2MeSADP to P2Y12 receptors in vitro (IC50=17 nM).,"SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,17,22006,DB00758,Clopidogrel
,25064036,IC50,"It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50=108 and 62 nM, respectively).","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,108,22007,DB00758,Clopidogrel
,25064036,IC50,"It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50=108 and 62 nM, respectively).","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,62,22008,DB00758,Clopidogrel
,25064036,ED50,Pre-clinical study of SAR216471 in a rat shunt thrombosis model demonstrated a dose-dependent antithrombotic activity after oral administration (ED50=6.7 mg/kg).,"SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],6.7,22009,DB00758,Clopidogrel
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],6.3,22010,DB00758,Clopidogrel
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],0.35,22011,DB00758,Clopidogrel
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],2.6,22012,DB00758,Clopidogrel
,21318583,inhibitory constant,"With an inhibitory constant of 0.08 nM for human FXa, apixaban has greater than 30,000-fold selectivity for FXa over other human coagulation proteases.","Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318583/),nM,0.08,24193,DB00758,Clopidogrel
,21318583,association rate constant,It produces a rapid onset of inhibition of FXa with association rate constant of 20 μM⁻¹/s approximately and inhibits free as well as prothrombinase- and clot-bound FXa activity in vitro.,"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318583/),[μM⁻¹] / [s],20,24194,DB00758,Clopidogrel
,31468659,area under the plasma-concentration-time curve (AUC0-24 ),Patients using clopidogrel had a mean predicted area under the plasma-concentration-time curve (AUC0-24 ) of 174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in patients without clopidogrel.,Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468659/),[h·ng] / [ml],174.7,24233,DB00758,Clopidogrel
,31468659,area under the plasma-concentration-time curve (AUC0-24 ),Patients using clopidogrel had a mean predicted area under the plasma-concentration-time curve (AUC0-24 ) of 174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in patients without clopidogrel.,Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468659/),[h·ng] / [ml],142.2,24234,DB00758,Clopidogrel
,20642549,t(max),"Ticagrelor was absorbed with median t(max) 1.5-3 h, exhibiting predictable pharmacokinetics over the 50-600 mg dose range.","Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642549/),h,1.5-3,25985,DB00758,Clopidogrel
,21827046,AUC(0-infinity),"The AUC(0-infinity) of CP was 13.78 +/- 0.67 and 11.46 +/- 1.98 ng/ mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [h·ml],13.78,27508,DB00758,Clopidogrel
,21827046,AUC(0-infinity),"The AUC(0-infinity) of CP was 13.78 +/- 0.67 and 11.46 +/- 1.98 ng/ mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [h·ml],11.46,27509,DB00758,Clopidogrel
,21827046,AUC(0-infinity),"The AUC(0-infinity) of IM was 33.08 +/- 5.76 and 21.67 +/- 8.95 microg/mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [h·ml],33.08,27510,DB00758,Clopidogrel
,21827046,AUC(0-infinity),"The AUC(0-infinity) of IM was 33.08 +/- 5.76 and 21.67 +/- 8.95 microg/mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [h·ml],21.67,27511,DB00758,Clopidogrel
,21827046,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [ml],3.81,27512,DB00758,Clopidogrel
,21827046,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [ml],3.18,27513,DB00758,Clopidogrel
,21827046,C(max),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [ml],3.42,27514,DB00758,Clopidogrel
,21827046,C(max),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [ml],2.08,27515,DB00758,Clopidogrel
,20533345,LOQ,The lower LOQ was 0.8 ng/mL.,Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533345/),[ng] / [ml],0.8,30466,DB00758,Clopidogrel
,18829199,recovery efficiencies,The derivatized samples were subjected to solid-phase extraction with a C2 disk plate and the overall procedure exhibited good reaction (more than 90%) and recovery efficiencies (from 85% to 105%).,Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829199/),%,85,30970,DB00758,Clopidogrel
,18829199,recovery efficiencies,The derivatized samples were subjected to solid-phase extraction with a C2 disk plate and the overall procedure exhibited good reaction (more than 90%) and recovery efficiencies (from 85% to 105%).,Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829199/),%,105,30971,DB00758,Clopidogrel
,25609600,flow rate,The system was operated at 25°C using a mobile phase consisting of acetonitrile and phosphate buffer (pH 3.0) in the gradient ratio at a flow rate of 1 mL min(-1) with ultraviolet detection monitored at 232 nm.,"Liquid Chromatographic Method for Simultaneous Quantitation of Clopidogrel, Aspirin and Atorvastatin in Rat Plasma and Its Application to the Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609600/),[ml] / [min],1,32433,DB00758,Clopidogrel
<,31189083,bioavailability,"Clopidogrel bisulfate (CB) is a golden antiplatelet treatment, yet its benefits are limited by its low bioavailability (<50%) caused by poor intestinal solubility and absorption.",Stabilizing excipients for engineered clopidogrel bisulfate procubosome derived in situ cubosomes for enhanced intestinal dissolution: Stability and bioavailability considerations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31189083/),%,50,32964,DB00758,Clopidogrel
,31189083,relative bioavailability,"Moreover, following oral administration in rabbits, CF2 showed higher relative bioavailability (153%) compared to commercial Plavix® with significant higher Cmax,shorter tmax, as well as enhanced antiplatelet activity.",Stabilizing excipients for engineered clopidogrel bisulfate procubosome derived in situ cubosomes for enhanced intestinal dissolution: Stability and bioavailability considerations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31189083/),%,153,32965,DB00758,Clopidogrel
,21656175,C(max),"The concentrations ranged up to 1,048.684 ng/mL, with a mean of 470.268 ng/mL, while clopidogrel had a mean C(max) of 1.348 ng/mL; these orders of magnitude show how much the back-conversion of this metabolite may influence clopidogrel quantification if it is not properly controlled.","Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656175/),[ng] / [ml],1.348,33006,DB00758,Clopidogrel
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 µl⋅min-1⋅mg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],2.42,34460,DB00758,Clopidogrel
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 µl⋅min-1⋅mg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],2.82,34461,DB00758,Clopidogrel
,29138287,CLint,"Of other enzymes displaying activity (UGT1A3, UGT1A9, UGT1A10-H, and UGT2B4), UGT2B4 (CLint,u 0.51 µl⋅min-1⋅mg-1) was estimated to contribute significantly to the hepatic clearance.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],0.51,34462,DB00758,Clopidogrel
,16977589,flow rate,The flow rate was set at 0.9 mL/min.,Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16977589/),[ml] / [min],0.9,34954,DB00758,Clopidogrel
,16977589,total run time of analysis,Ticlopidine was used as internal standard and the total run time of analysis was about 12 min.,Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16977589/),min,12,34955,DB00758,Clopidogrel
,16406450,flow rate,The flow rate was set at 0.2 mL/min.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),[ml] / [min],0.2,35009,DB00758,Clopidogrel
,16406450,time of analysis,Repaglinide was chosen as an internal standard and the time of analysis was 12 min.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),min,12,35010,DB00758,Clopidogrel
,16406450,extraction recovery,The extraction recovery of SR26334 from plasma was within the range of 85-90%.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),%,85-90,35011,DB00758,Clopidogrel
,34262326,area under the curve (AUC; 0-T,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [h·l],300.342,35155,DB00758,Clopidogrel
,34262326,AUC 0-∞,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [h·l],320.462,35156,DB00758,Clopidogrel
,34262326,plasma peak concentration,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [l],30.622,35157,DB00758,Clopidogrel
,34262326,peak time,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),h,7.954,35158,DB00758,Clopidogrel
,34262326,half-life,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),h,7.954,35159,DB00758,Clopidogrel
,21617016,k(tr),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],5.97,40381,DB00758,Clopidogrel
,21617016,k(e) (elimination rate constant),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],0.126,40382,DB00758,Clopidogrel
,21617016,k(d) (distribution rate constant),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],0.212,40383,DB00758,Clopidogrel
,21617016,V(2) (volume of central compartment),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),l,21.0,40384,DB00758,Clopidogrel
,21617016,V(3) (volume of peripheral compartment),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),l,38.8,40385,DB00758,Clopidogrel
,21617016,k(in) (input rate),"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],27.9,40386,DB00758,Clopidogrel
,21617016,E(max) (maximum effect on input rate),"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],0.292,40387,DB00758,Clopidogrel
,21617016,EC(5) (0),"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),[ng] / [ml],0.00629,40388,DB00758,Clopidogrel
,21617016,effective concentration,"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),[ng] / [ml],0.00629,40389,DB00758,Clopidogrel
,20171421,C(max),"The geometric mean C(max) for the test and reference formulations was 877.76 and 913.49 pg/mL, respectively.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[pg] / [ml],877.76,50402,DB00758,Clopidogrel
,20171421,C(max),"The geometric mean C(max) for the test and reference formulations was 877.76 and 913.49 pg/mL, respectively.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[pg] / [ml],913.49,50403,DB00758,Clopidogrel
,20171421,AUC(0-t),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],1911.53,50404,DB00758,Clopidogrel
,20171421,AUC(0-t),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2053.09,50405,DB00758,Clopidogrel
,20171421,AUC(0-infinity)),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2021.33,50406,DB00758,Clopidogrel
,20171421,AUC(0-infinity)),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2188.25,50407,DB00758,Clopidogrel
more,15935741,extraction efficiency,The extraction efficiency for the carboxylic acid metabolite of clopidogrel was more than 85.76%.,Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15935741/),%,85.76,56303,DB00758,Clopidogrel
,10440423,Cmax,"For the fed/fasting study, mean Cmax values (+/-SD) were 2.7+/-0.62 mg/L and 2.1+/-0.96 mg/L for the fasting state and the fed state, respectively and the 90% CI of Cmax ratio was [0.57 - 0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.7,58522,DB00758,Clopidogrel
,10440423,Cmax,"For the fed/fasting study, mean Cmax values (+/-SD) were 2.7+/-0.62 mg/L and 2.1+/-0.96 mg/L for the fasting state and the fed state, respectively and the 90% CI of Cmax ratio was [0.57 - 0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.1,58523,DB00758,Clopidogrel
,10440423,AUC(0-obs),"Mean AUC(0-obs) values (AUC to the last observed value) were 7.1+/-1.6 mg.h/L and 7.4+/-1.64 mg.h/L, respectively, and the 90% Cl of AUC ratios were [0.90 - 1.02] and [0.89 - 0.97], respectively.",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],7.1,58524,DB00758,Clopidogrel
,10440423,AUC(0-obs),"Mean AUC(0-obs) values (AUC to the last observed value) were 7.1+/-1.6 mg.h/L and 7.4+/-1.64 mg.h/L, respectively, and the 90% Cl of AUC ratios were [0.90 - 1.02] and [0.89 - 0.97], respectively.",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],7.4,58525,DB00758,Clopidogrel
,10440423,Cmax,"For the antacid study, mean Cmax values were 2.6+/-0.84 mg/L and 2.5+/-0.87 mg/L for the no-antacid regimen and the antacid regimen, respectively, and the 90% CI of Cmax ratio was [0.74 - 1.16].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.6,58526,DB00758,Clopidogrel
,10440423,Cmax,"For the antacid study, mean Cmax values were 2.6+/-0.84 mg/L and 2.5+/-0.87 mg/L for the no-antacid regimen and the antacid regimen, respectively, and the 90% CI of Cmax ratio was [0.74 - 1.16].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.5,58527,DB00758,Clopidogrel
,10440423,AUC(0-obs),"Mean AUC(0-obs) values were 6.3+/-1.34 mg.h/L and 5.8+/-1.33 mg.h/L, respectively, and the 90% CI of AUC ratios was [0.89+/-0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],6.3,58528,DB00758,Clopidogrel
,10440423,AUC(0-obs),"Mean AUC(0-obs) values were 6.3+/-1.34 mg.h/L and 5.8+/-1.33 mg.h/L, respectively, and the 90% CI of AUC ratios was [0.89+/-0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],5.8,58529,DB00758,Clopidogrel
,19496900,peak,"Plasma SR26334 concentrations peaked earlier after crushed delivery than after oral intake (44 vs. 70 minutes, P = 0.023) and the median peak was 80% higher (13,083 vs. 7,255 ng/mL, respectively, P = 0.021).",Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19496900/),[ng] / [ml],"13,083",65198,DB00758,Clopidogrel
,19496900,peak,"Plasma SR26334 concentrations peaked earlier after crushed delivery than after oral intake (44 vs. 70 minutes, P = 0.023) and the median peak was 80% higher (13,083 vs. 7,255 ng/mL, respectively, P = 0.021).",Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19496900/),[ng] / [ml],"7,255",65199,DB00758,Clopidogrel
,26576037,maximal concentration (Cmax ),"CAM reached maximal concentration (Cmax ) (median, 110.8 nm; range, 41.9-484.8) 0.5-2 h after the loading dose.",Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26576037/),nm,110.8,66213,DB00758,Clopidogrel
,26576037,IC50,"A sigmoid dose-response curve defined the relations between CAMCmax and PRI after 3 to 24 h (IC50 , 459.6 nm; 95% confidence interval, 453.4-465.7; R(2) = 0.82).",Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26576037/),nm,459.6,66214,DB00758,Clopidogrel
,27459888,Cmax,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],0.4,68425,DB00758,Clopidogrel
,27459888,Cmax,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],1.7,68426,DB00758,Clopidogrel
,27459888,AUC0-∞,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [mlh],0.9,68427,DB00758,Clopidogrel
,27459888,AUC0-∞,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [mlh],2.0,68428,DB00758,Clopidogrel
,27459888,Cmax,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],8.2,68429,DB00758,Clopidogrel
,27459888,Cmax,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],2.8,68430,DB00758,Clopidogrel
,27459888,AUC0-∞,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ngh] / [ml],18.2,68431,DB00758,Clopidogrel
,27459888,AUC0-∞,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ngh] / [ml],6.4,68432,DB00758,Clopidogrel
,27459888,IC50,"In rat liver microsomes, DZSM inhibited clopidogrel metabolism with an IC50 of 0.02mg/mL.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[mg] / [ml],0.02,68433,DB00758,Clopidogrel
,33486718,apparent clearance,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),[l] / [h],1.1,74526,DB00758,Clopidogrel
,33486718,apparent central,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),l,14.9,74527,DB00758,Clopidogrel
,33486718,peripheral volumes of distribution,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),l,9.5,74528,DB00758,Clopidogrel
,10761167,in,"At Day 10, there was not a statistically significant difference in mean inhibition of platelet aggregation (49.2% +/- 38.6% in cirrhotics vs. 66.7% +/- 7.5% in normals) or in bleeding time prolongation factor (1.64 +/- 0.49 in cirrhotics vs. 1.54 +/- 0.87 in normals) between groups.",Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761167/),%,49.2,75146,DB00758,Clopidogrel
,10761167,in,"At Day 10, there was not a statistically significant difference in mean inhibition of platelet aggregation (49.2% +/- 38.6% in cirrhotics vs. 66.7% +/- 7.5% in normals) or in bleeding time prolongation factor (1.64 +/- 0.49 in cirrhotics vs. 1.54 +/- 0.87 in normals) between groups.",Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761167/),%,66.,75147,DB00758,Clopidogrel
,23016454,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax) was higher in the 681GA+681AA group than that in the 681GG group (1.93 +/- 1.77 vs. 1.65 +/- 1.56ng/mL, P=0.613).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[ng] / [ml],1.93,79108,DB00758,Clopidogrel
,23016454,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax) was higher in the 681GA+681AA group than that in the 681GG group (1.93 +/- 1.77 vs. 1.65 +/- 1.56ng/mL, P=0.613).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[ng] / [ml],1.65,79109,DB00758,Clopidogrel
,23016454,area under the curve to the last measurable concentration (AUC(0-36)),The area under the curve to the last measurable concentration (AUC(0-36)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of clopidogrel were lower in the 681GG group than that in the 681GA+ 681AA group (2.25 +/- 1.64 vs.,CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),,2.25,79110,DB00758,Clopidogrel
,23016454,oral clearance (CI/F),"The oral clearance (CI/F) was lower in the 681GA+681AA group than that in the 681GG group (51.96 +/- 36.13 vs. 54.47 +/- 35.21 x 10(3) L/h, P=0.829).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[l] / [h],51.96,79111,DB00758,Clopidogrel
,23016454,oral clearance (CI/F),"The oral clearance (CI/F) was lower in the 681GA+681AA group than that in the 681GG group (51.96 +/- 36.13 vs. 54.47 +/- 35.21 x 10(3) L/h, P=0.829).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[l] / [h],54.47,79112,DB00758,Clopidogrel
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),min,30,79419,DB00758,Clopidogrel
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),h,1.5,79420,DB00758,Clopidogrel
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,84.1,79421,DB00758,Clopidogrel
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,48.9,79422,DB00758,Clopidogrel
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,78.8,79423,DB00758,Clopidogrel
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,35.0,79424,DB00758,Clopidogrel
,22489610,time to maximum concentration,"Ticagrelor is rapidly absorbed, with a median time to maximum concentration of 1.3-2.0 hours.","Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22489610/),h,1.3-2.0,79556,DB00758,Clopidogrel
,15497667,AUC0-inf,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],29.94,90435,DB00758,Clopidogrel
,15497667,AUC0-t,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],29.53,90436,DB00758,Clopidogrel
,15497667,AUC0-t,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],29.24,90437,DB00758,Clopidogrel
,15497667,AUC0-t,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],28.83,90438,DB00758,Clopidogrel
,15497667,Cmax,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[ng] / [ml],7.386,90439,DB00758,Clopidogrel
,15497667,Cmax,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[ng] / [ml],7.921,90440,DB00758,Clopidogrel
,15497667,Tmax,The median Tmax for both formulations was 1.25 h.,Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),h,1.25,90441,DB00758,Clopidogrel
,27774067,clearance,"It was shown that the cleavage of vicagrel was almost completed in intestine with great different clearance (53.28 vs. 3.643 L⋅h-1⋅kg-1, p < 0.05) in rats and dogs.","Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774067/),[l] / [h·kg],53.28,92770,DB00758,Clopidogrel
,27774067,clearance,"It was shown that the cleavage of vicagrel was almost completed in intestine with great different clearance (53.28 vs. 3.643 L⋅h-1⋅kg-1, p < 0.05) in rats and dogs.","Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774067/),[l] / [h·kg],3.643,92771,DB00758,Clopidogrel
,27774067,clearance,"With no further hydrolysis to CAM, the greatest clearance of AM (3.26 mL⋅h-1⋅kg-1) was found in dog intestine.","Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774067/),[ml] / [h·kg],3.26,92772,DB00758,Clopidogrel
,27774067,production velocity,"Albeit similar hydrolysis clearance and AM production was observed among hepatic microsomes of the three species, the production velocity of CAM ranked highest in dogs (7.55 pmol/min/mg protein).","Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel. ",Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774067/),[pM] / [mg·min],7.55,92773,DB00758,Clopidogrel
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.0,96562,DB00758,Clopidogrel
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.25,96563,DB00758,Clopidogrel
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,0.5,96564,DB00758,Clopidogrel
,33244163,Tmax,"Vicagrel absorption was fast (Tmax = 0.625 h), and the mean t1/2 of vicagrel-related components was ~38.0 h in both plasma and blood.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),h,0.625,110389,DB00758,Clopidogrel
,33244163,t1/2,"Vicagrel absorption was fast (Tmax = 0.625 h), and the mean t1/2 of vicagrel-related components was ~38.0 h in both plasma and blood.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),h,38.0,110390,DB00758,Clopidogrel
,33244163,blood-to-plasma radioactivity AUCinf ratio,"The blood-to-plasma radioactivity AUCinf ratio was 0.55, suggesting preferential distribution of drug-related material in plasma.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),,0.55,110391,DB00758,Clopidogrel
,33244163,cumulative excreted radioactivity,"At 168 h after oral administration, the mean cumulative excreted radioactivity was 96.71% of the dose, including 68.03% in urine and 28.67% in feces.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),,68,110392,DB00758,Clopidogrel
,33244163,cumulative excreted radioactivity,"At 168 h after oral administration, the mean cumulative excreted radioactivity was 96.71% of the dose, including 68.03% in urine and 28.67% in feces.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),%,28,110393,DB00758,Clopidogrel
,11095576,half-lives,"Nonenzymatic chiral inversion of clopidogrel at 37 degrees C in 0.1 M phosphate buffers could be observed but was found to be slow, with estimated half-lives of 7 to 12 days, depending on the pH.",Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095576/),d,7 to 12,113210,DB00758,Clopidogrel
,17112805,flux,Inhibition of P-gp activity by different modulators increased the absorptive clopidogrel flux across Caco-2 monolayers from 0.51+/-0.19 pmol/cm2 (mean+/-SD) at baseline by a maximum of 5- to 9-fold (P<.001) and the intracellular accumulation from 0.99+/-0.11 pmol/mg protein by a maximum of 2.5-fold (P<.001) in response to 1-micromol/L clopidogrel and decreased clopidogrel efflux to the level of passive diffusion.,Impact of P-glycoprotein on clopidogrel absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[pM] / [cm2],0.51,118395,DB00758,Clopidogrel
,17112805,intracellular accumulation,Inhibition of P-gp activity by different modulators increased the absorptive clopidogrel flux across Caco-2 monolayers from 0.51+/-0.19 pmol/cm2 (mean+/-SD) at baseline by a maximum of 5- to 9-fold (P<.001) and the intracellular accumulation from 0.99+/-0.11 pmol/mg protein by a maximum of 2.5-fold (P<.001) in response to 1-micromol/L clopidogrel and decreased clopidogrel efflux to the level of passive diffusion.,Impact of P-glycoprotein on clopidogrel absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[pM] / [mg],0.99,118396,DB00758,Clopidogrel
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],13.3,118397,DB00758,Clopidogrel
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],2.5,118398,DB00758,Clopidogrel
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],49.7,118399,DB00758,Clopidogrel
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],6.6,118400,DB00758,Clopidogrel
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],1502,118401,DB00758,Clopidogrel
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],209,118402,DB00758,Clopidogrel
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],7057,118403,DB00758,Clopidogrel
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],744,118404,DB00758,Clopidogrel
,17220050,t1/2,The t1/2 increased from 2.5 h in the fasted state to 5.0 h in the fed state.,Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220050/),h,2.5,122414,DB00758,Clopidogrel
,17220050,t1/2,The t1/2 increased from 2.5 h in the fasted state to 5.0 h in the fed state.,Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220050/),h,5.0,122415,DB00758,Clopidogrel
greater,20346740,recovery,SPE recovery of the analytes from plasma and urine was comparable and greater than 80%.,Capillary zone electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20346740/),%,80,127016,DB00758,Clopidogrel
,15821819,half-life,The half-life of intravenous dalteparin is 77 minutes with slight dose-related variation.,High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15821819/),min,77,128078,DB00758,Clopidogrel
,28914344,area under the time-concentration curve,"As a result, predicted area under the time-concentration curve values was lower in carriers of this allele, with median 5.94 ng h/ml (interquartile range 3.92-12.51 [ng∙h/ml]) vs. 12.70 ng h/ml in non-carriers (interquartile range, 7.00-19.39 [ng∙h/ml]), respectively (p = 0.004).",Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28914344/),[h·ng] / [ml],5.94,129747,DB00758,Clopidogrel
,28914344,area under the time-concentration curve,"As a result, predicted area under the time-concentration curve values was lower in carriers of this allele, with median 5.94 ng h/ml (interquartile range 3.92-12.51 [ng∙h/ml]) vs. 12.70 ng h/ml in non-carriers (interquartile range, 7.00-19.39 [ng∙h/ml]), respectively (p = 0.004).",Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28914344/),[h·ng] / [ml],12.70,129748,DB00758,Clopidogrel
,26681020,peak plasma concentration (Cmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[ng] / [ml],1351.101,131846,DB00758,Clopidogrel
,26681020,peak plasma concentration (Cmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[ng] / [ml],1184.652,131847,DB00758,Clopidogrel
,26681020,area under the curve,"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[h·ng] / [ml],2642.017,131848,DB00758,Clopidogrel
,26681020,area under the curve,"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[h·ng] / [ml],2780.666,131849,DB00758,Clopidogrel
,26681020,time to reach Cmax (Tmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),h,0.789,131850,DB00758,Clopidogrel
,26681020,time to reach Cmax (Tmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),h,0.953,131851,DB00758,Clopidogrel
,26681020,relative bioavailability,"The relative bioavailability of the formulation was 101.7 ± 35.3%, which indicated that the test preparation was bioequivalent to the reference drug.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),%,101.7,131852,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,286.2,136488,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,105.0,136489,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,264.2,136490,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,83.0,136491,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,854.4,136492,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,286.0,136493,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,322.1,136494,DB00758,Clopidogrel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,184.1,136495,DB00758,Clopidogrel
,18365698,hight,"When clopidogrel resinate was treated onto Caco-2 cell monolayers, clopidogrel, but not the resin, permeated across the cells with a hight permeation coefficient (Papp) of 13.5 +/- 1.13 x 10(-6) cm/sec.",The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365698/),[cm] / [s],13.5,156086,DB00758,Clopidogrel
,18365698,permeation coefficient (Papp),"When clopidogrel resinate was treated onto Caco-2 cell monolayers, clopidogrel, but not the resin, permeated across the cells with a hight permeation coefficient (Papp) of 13.5 +/- 1.13 x 10(-6) cm/sec.",The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365698/),[cm] / [s],13.5,156087,DB00758,Clopidogrel
,28921624,time to reach maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),h,8,162329,DB00758,Clopidogrel
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],355,162330,DB00758,Clopidogrel
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],63.20,162331,DB00758,Clopidogrel
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.67,162332,DB00758,Clopidogrel
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.53,162333,DB00758,Clopidogrel
,21696537,area under the,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,54,166599,DB00758,Clopidogrel
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,66.3,166600,DB00758,Clopidogrel
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,47,166601,DB00758,Clopidogrel
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,59.7,166602,DB00758,Clopidogrel
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,68.9,166603,DB00758,Clopidogrel
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,64.5,166604,DB00758,Clopidogrel
,21704146,time to peak plasma concentration (T(max)),FA was rapidly absorbed following oral administration with a mean time to peak plasma concentration (T(max)) of 0.03 h.,Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704146/),h,0.03,166719,DB00758,Clopidogrel
,21704146,maximum plasma concentration (C(max)),The corresponding maximum plasma concentration (C(max)) and the area under the concentration-time curve (AUC) were 8174.55 ng/L and 2594.45 h ng/mL respectively.,Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704146/),[ng] / [l],8174.55,166720,DB00758,Clopidogrel
,21704146,area under the concentration-time curve (AUC),The corresponding maximum plasma concentration (C(max)) and the area under the concentration-time curve (AUC) were 8174.55 ng/L and 2594.45 h ng/mL respectively.,Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704146/),[h·ng] / [ml],2594.45,166721,DB00758,Clopidogrel
,18613862,AUC(0-->infinity),"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [h·ml],6.24,170091,DB00758,Clopidogrel
,18613862,AUC(0-->infinity),"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [h·ml],8.93,170092,DB00758,Clopidogrel
,18613862,half-life,"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),,5.46,170093,DB00758,Clopidogrel
,18613862,half-life,"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),,8.43,170094,DB00758,Clopidogrel
,18613862,C(max),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [ml],3.09,170095,DB00758,Clopidogrel
,18613862,T(max),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),h,0.76,170096,DB00758,Clopidogrel
,18613862,AUC(0-->infinity),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [h·ml],7.98,170097,DB00758,Clopidogrel
,18613862,t(1/2e),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),h,7.38,170098,DB00758,Clopidogrel
,15578632,chromatographic run time,The method had a chromatographic run time of 3.0 min and a linear calibration curve over the range 1.0-1000 ng ml(-1) (r(2) > 0.999427).,Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578632/),min,3.0,175837,DB00758,Clopidogrel
,15578632,limit of quant,The limit of quantification was 1.0 ng ml(-1).,Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578632/),[ng] / [ml],1.0,175838,DB00758,Clopidogrel
,33493742,flow rate,"The chromatographic separation was achieved on an Ultron ES-OVM column (150 × 2.0 mm, 5 μm) with acetonitrile-ammonium acetate (10 mM, pH 4.5) (22:78, v/v) at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for the enantioseparation and determination of clopidogrel bisulfate in beagle plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493742/),[ml] / [min],0.3,176338,DB00758,Clopidogrel
>,33493742,extraction recovery,The extraction recovery was >90.2 % and no obvious matrix effect was observed.,Development and validation of a LC-MS/MS method for the enantioseparation and determination of clopidogrel bisulfate in beagle plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493742/),%,90.2,176339,DB00758,Clopidogrel
,19446152,C(max),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [ml],5.2,177642,DB00758,Clopidogrel
,19446152,T(max),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),h,0.9,177643,DB00758,Clopidogrel
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [h·ml],10.1,177644,DB00758,Clopidogrel
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [ml],5.4,177645,DB00758,Clopidogrel
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),h,0.9,177646,DB00758,Clopidogrel
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [h·ml],10.3,177647,DB00758,Clopidogrel
,19446152,Cmax,"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [ml],10.9,177648,DB00758,Clopidogrel
,19446152,AUC(0-t),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],38.8,177649,DB00758,Clopidogrel
,19446152,AUC(0-t),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],40.6,177650,DB00758,Clopidogrel
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],43.0,177651,DB00758,Clopidogrel
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [ml],11.9,177652,DB00758,Clopidogrel
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],40.6,177653,DB00758,Clopidogrel
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],43.8,177654,DB00758,Clopidogrel
,19446152,maximal antiplatelet effect (Emax),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,58.8,177655,DB00758,Clopidogrel
,19446152,maximal antiplatelet effect (Emax),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,61.7,177656,DB00758,Clopidogrel
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,4299.1,177657,DB00758,Clopidogrel
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,61.7,177658,DB00758,Clopidogrel
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,4406.9,177659,DB00758,Clopidogrel
,22782539,bioavailability,"Similarly, clopidogrel bioavailability remained unchanged by chronic administration of dabigatran etexilate (part 3: ratio test/reference for AUC(0-24) was 103%; 90% CI 80.3-131%), as did its pharmacodynamic effects on the inhibition of platelet aggregation.",Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22782539/),%,103,180838,DB00758,Clopidogrel
,26071277,Emax,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),%,56,183118,DB00758,Clopidogrel
,26071277,EAUC50,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),[h·μg] / [l],15.9,183119,DB00758,Clopidogrel
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],45.39,190502,DB00758,Clopidogrel
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],29.15,190503,DB00758,Clopidogrel
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],19.55,190504,DB00758,Clopidogrel
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],61.05,190505,DB00758,Clopidogrel
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],37.67,190506,DB00758,Clopidogrel
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],27.08,190507,DB00758,Clopidogrel
,25577873,K12,"The population typical values of K12, CL/F, V/F, EC50, K(in), and E(max) were 0.259 h(-1), 179 L x h(-1), 632 L, 1.57 ng x mL(-1), 4.29 and 0.664, respectively.",[Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25577873/),1/[h],0.259,192051,DB00758,Clopidogrel
,25577873,E(max),"The population typical values of K12, CL/F, V/F, EC50, K(in), and E(max) were 0.259 h(-1), 179 L x h(-1), 632 L, 1.57 ng x mL(-1), 4.29 and 0.664, respectively.",[Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25577873/),,0.664,192052,DB00758,Clopidogrel
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,31,195243,DB00758,Clopidogrel
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,25,195244,DB00758,Clopidogrel
,26080512,Cmax,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [l],1.97,200543,DB00758,Clopidogrel
,26080512,Cmax,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [l],2.48,200544,DB00758,Clopidogrel
,26080512,AUC0-∞,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [h·l],8.44,200545,DB00758,Clopidogrel
,26080512,AUC0-∞,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [h·l],14.38,200546,DB00758,Clopidogrel
,20206794,ma,"In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing.",Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206794/),%,87,205173,DB00758,Clopidogrel
,20206794,maximal IPA,"After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours.",Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206794/),%,58,205174,DB00758,Clopidogrel
,23016453,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration versus time curve from time 0 h to 36 h (AUC(0-36)), elimination half-life (t1/2), clearance rate (CL/F) and apparent volume of distribution (Vd) were (1.804 +/- 1.706) ng/ml, (0.7 +/- 0.3) h, (2.465 +/- 1.693) ng x h/ml, (7.3 +/- 7.0) h, (53.09 +/- 34.65) x 10(3) L/h and (447.1 +/- 440.8) x 10(3) L, respectively.",Pharmacokinetics of clopidogrel in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016453/),[ng] / [ml],1.804,206250,DB00758,Clopidogrel
,23016453,apparent volume of distribution (Vd),"The peak plasma concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration versus time curve from time 0 h to 36 h (AUC(0-36)), elimination half-life (t1/2), clearance rate (CL/F) and apparent volume of distribution (Vd) were (1.804 +/- 1.706) ng/ml, (0.7 +/- 0.3) h, (2.465 +/- 1.693) ng x h/ml, (7.3 +/- 7.0) h, (53.09 +/- 34.65) x 10(3) L/h and (447.1 +/- 440.8) x 10(3) L, respectively.",Pharmacokinetics of clopidogrel in healthy Chinese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016453/),l,447.1,206251,DB00758,Clopidogrel
,30326264,tmax,"In the single-ascending-dose study, vicagrel was metabolized rapidly with the median tmax for the three metabolites, namely, H4, H3, and SM3, ranging from 0.25-1.75 h.","Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.25-1.75,207785,DB00758,Clopidogrel
,30326264,tmax,The median tmax for active H4 in the vicagrel 5 mg group was slightly shorter than that in the clopidogrel 75 mg group (0.50 versus 0.75 h).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.50,207786,DB00758,Clopidogrel
,30326264,tmax,The median tmax for active H4 in the vicagrel 5 mg group was slightly shorter than that in the clopidogrel 75 mg group (0.50 versus 0.75 h).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.75,207787,DB00758,Clopidogrel
,30326264,AUC0-t,The mean AUC0-t for H4 in the vicagrel 5 mg group was similar to that in the clopidogrel 75 mg group (11.7 versus 11.8 ng∙h/mL).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),[ng∙h] / [ml],11.7,207788,DB00758,Clopidogrel
,30326264,AUC0-t,The mean AUC0-t for H4 in the vicagrel 5 mg group was similar to that in the clopidogrel 75 mg group (11.7 versus 11.8 ng∙h/mL).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),[ng∙h] / [ml],11.8,207789,DB00758,Clopidogrel
,30326264,tmax,"In the loading-dose study, for active H4, the median tmax was slightly shorter (0.50 versus 0.75 h) and the mean AUC0-t was 29% higher in the vicagrel 20 mg group than those in the clopidogrel 300 mg group.","Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.50,207790,DB00758,Clopidogrel
,30326264,tmax,"In the loading-dose study, for active H4, the median tmax was slightly shorter (0.50 versus 0.75 h) and the mean AUC0-t was 29% higher in the vicagrel 20 mg group than those in the clopidogrel 300 mg group.","Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.75,207791,DB00758,Clopidogrel
<,27511819,time to maximal plasma concentration,"Results from pharmacokinetic (PK) studies showed that ClopNPT released the active metabolite with a time to maximal plasma concentration of <5 minutes in C57BL/6 mice after either oral or intravenous administration, and plasma concentrations of the active metabolite reached Cmax values of 1242 and 1100 ng/ml after a 10-mg/kg oral dose and a 5-mg/kg intravenous dose, respectively.",Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511819/),min,5,209096,DB00758,Clopidogrel
,27511819,Cmax,"Results from pharmacokinetic (PK) studies showed that ClopNPT released the active metabolite with a time to maximal plasma concentration of <5 minutes in C57BL/6 mice after either oral or intravenous administration, and plasma concentrations of the active metabolite reached Cmax values of 1242 and 1100 ng/ml after a 10-mg/kg oral dose and a 5-mg/kg intravenous dose, respectively.",Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511819/),[ng] / [ml],1242,209097,DB00758,Clopidogrel
,27511819,Cmax,"Results from pharmacokinetic (PK) studies showed that ClopNPT released the active metabolite with a time to maximal plasma concentration of <5 minutes in C57BL/6 mice after either oral or intravenous administration, and plasma concentrations of the active metabolite reached Cmax values of 1242 and 1100 ng/ml after a 10-mg/kg oral dose and a 5-mg/kg intravenous dose, respectively.",Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511819/),[ng] / [ml],1100,209098,DB00758,Clopidogrel
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],12.8,212063,DB00758,Clopidogrel
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],17.9,212064,DB00758,Clopidogrel
,26068527,AUC0-t,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],9850,212918,DB00758,Clopidogrel
,26068527,AUC0-t,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],"27,300",212919,DB00758,Clopidogrel
,26068527,AUC0-∞,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],9850,212920,DB00758,Clopidogrel
,26068527,AUC0-∞,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],"27,600",212921,DB00758,Clopidogrel
,26068527,t1/2,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),h,2.07,212922,DB00758,Clopidogrel
,26068527,t1/2,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),h,7.49,212923,DB00758,Clopidogrel
,26068527,VLz/F,The pharmacokinetic data for clopidogrel carboxylic acid showed significant decreases in VLz/F (from 0.765±0.299 to 0.256±0.0594 l/kg; p<0.05) after pretreatment with high dose of fluvoxamine.,Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[l] / [kg],0.765,212924,DB00758,Clopidogrel
,26068527,VLz/F,The pharmacokinetic data for clopidogrel carboxylic acid showed significant decreases in VLz/F (from 0.765±0.299 to 0.256±0.0594 l/kg; p<0.05) after pretreatment with high dose of fluvoxamine.,Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[l] / [kg],0.256,212925,DB00758,Clopidogrel
,29154109,flow rate,"The mobile phase was acetonitrile-water-formic acid (45:55:0.0275, v/v/v) delivered at a flow rate of 0.45mL/min under isocratic elution.",Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29154109/),[ml] / [min],0.45,213288,DB00758,Clopidogrel
,29154109,total chromatographic run time,The total chromatographic run time was 6min.,Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29154109/),min,6,213289,DB00758,Clopidogrel
,31034271,Time to maximum concentration,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.54,213428,DB00758,Clopidogrel
,31034271,Time to maximum concentration,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.71,213429,DB00758,Clopidogrel
,31034271,terminal-phase half-life,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,1.81,213430,DB00758,Clopidogrel
,31034271,terminal-phase half-life,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.97,213431,DB00758,Clopidogrel
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,15.8,213950,DB00758,Clopidogrel
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,11.6,213951,DB00758,Clopidogrel
,19698014,time to peak plasma concentration,"Absorption is complete and rapid, with mean time to peak plasma concentration of approximately 30 minutes for R-138727.","Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698014/),min,30,217918,DB00758,Clopidogrel
,19698014,plasma half-life,"Median plasma half-life of the active metabolite is approximately 4 hours, and excretion is mainly urinary.","Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698014/),h,4,217919,DB00758,Clopidogrel
,22169056,run time,"The method was validated across the clinically relevant concentration range of 0.01-50 ng/mL for parent clopidogrel and 0.1-150 ng/mL (r(2)=0.99) for CAMD, with a fast run time of 1.5 min to support pharmacokinetic studies using 75, 150, or 300 mg oral doses of clopidogrel.",A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169056/),min,1.5,219562,DB00758,Clopidogrel
,26825365,time to maximal plasma clopidogrel concentration (t max),"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,0.83,220348,DB00758,Clopidogrel
,26825365,time to maximal plasma clopidogrel concentration (t max),"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,0.91,220349,DB00758,Clopidogrel
,26825365,terminal elimination half-life,"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,3.99,220350,DB00758,Clopidogrel
,26825365,terminal elimination half-life,"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,3.51,220351,DB00758,Clopidogrel
,20594086,maximum concentration,"Clopidogrel was not detected in any samples; in dogs given 1.13 +/- 0.17 mg/kg, maximum concentration of SR 26334 (mean +/- SD, 0.206 +/- 0.2 microg/mL) was detected 1 hour after administration.",Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594086/),[μg] / [ml],0.206,221241,DB00758,Clopidogrel
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,171.4,221656,DB00758,Clopidogrel
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,146.3,221657,DB00758,Clopidogrel
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,173.7,221658,DB00758,Clopidogrel
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,157.3,221659,DB00758,Clopidogrel
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,322.2,225780,DB00758,Clopidogrel
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,211.9,225781,DB00758,Clopidogrel
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,264.1,225782,DB00758,Clopidogrel
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,125.1,225783,DB00758,Clopidogrel
,17472221,total analytical run time,"The total analytical run time was relatively short (3 min), and the LLOQ was 10 pg/mL using 0.5 mL of human plasma.",Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),min,3,225784,DB00758,Clopidogrel
,28692105,effective plasma levels,"Low effective plasma levels of prasugrel active metabolite were measured at trough [0.5 (quartiles 0.5-1.1) ng/ml at baseline], and 2 hours after intake [5.7 (3.8-9.8) ng/ml], but showed coefficients of variation of ~70 %.",Prasugrel in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692105/),[ng] / [ml],0.5,228162,DB00758,Clopidogrel
,28692105,effective plasma levels,"Low effective plasma levels of prasugrel active metabolite were measured at trough [0.5 (quartiles 0.5-1.1) ng/ml at baseline], and 2 hours after intake [5.7 (3.8-9.8) ng/ml], but showed coefficients of variation of ~70 %.",Prasugrel in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692105/),[ng] / [ml],5.7,228163,DB00758,Clopidogrel
,25557828,AM,"Clopidogrel AM levels were similar in patients randomized to aspirin 325 or 81 mg (geometric mean, 12.70 ng mL(-1) ; 95% CI, 10.96-14.72 ng mL(-1) ; and geometric mean, 12.55 ng mL(-1) ; 95% CI, 10.80-14.58 ng mL(-1) ; P = 0.91).",Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557828/),[ng] / [ml],12.70,229330,DB00758,Clopidogrel
,25557828,AM,"Clopidogrel AM levels were similar in patients randomized to aspirin 325 or 81 mg (geometric mean, 12.70 ng mL(-1) ; 95% CI, 10.96-14.72 ng mL(-1) ; and geometric mean, 12.55 ng mL(-1) ; 95% CI, 10.80-14.58 ng mL(-1) ; P = 0.91).",Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557828/),[ng] / [ml],12.55,229331,DB00758,Clopidogrel
,26446447,unbound paclitaxel clearance,"Estimated unbound paclitaxel clearance was 238 l h−1, which was only 62% of the cohort geometric mean (385 l h−1; range 176–726).",Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446447/),[l] / [h],238,240673,DB00758,Clopidogrel
,26446447,unbound paclitaxel clearance,"Estimated unbound paclitaxel clearance was 238 l h−1, which was only 62% of the cohort geometric mean (385 l h−1; range 176–726).",Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446447/),[l] / [h],385,240674,DB00758,Clopidogrel
,19634510,AUCinf,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],15773,241654,DB00758,Clopidogrel
,19634510,AUCinf,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],15691,241655,DB00758,Clopidogrel
,19634510,AUCt,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],"15,462",241656,DB00758,Clopidogrel
,19634510,AUCt,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],"15,315",241657,DB00758,Clopidogrel
,19634510,Cmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[ng] / [ml],4919,241658,DB00758,Clopidogrel
,19634510,Cmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[ng] / [ml],4699,241659,DB00758,Clopidogrel
,19634510,tmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.84,241660,DB00758,Clopidogrel
,19634510,tmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.93,241661,DB00758,Clopidogrel
,19634510,t1/2,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,7.92,241662,DB00758,Clopidogrel
,19634510,t1/2,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,8.41,241663,DB00758,Clopidogrel
,19634510,AUCinf,Pharmacokinetic parameters values of CBS were: AUCinf: 1.96 vs.,Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,1.96,241664,DB00758,Clopidogrel
,19634510,AUCt,"1.84 ng x h/mL (test vs reference), AUCt: 1.91 vs.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,1.91,241665,DB00758,Clopidogrel
,19634510,Cmax,"1.81 ng x h/mL, Cmax, 1.44 vs.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,1.44,241666,DB00758,Clopidogrel
,19634510,tmax,"1.52 ng/mL, tmax: 0.90 vs.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,0.90,241667,DB00758,Clopidogrel
,19634510,t1/2,"0.99 h, t1/2: 0.74 vs. 0.57 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.74,241668,DB00758,Clopidogrel
,19634510,t1/2,"0.99 h, t1/2: 0.74 vs. 0.57 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.57,241669,DB00758,Clopidogrel
,10440420,Cmax,A Cmax of 3.9 mg-Eqv/L was reached after a median time of 1 hour (Tmax).,Pharmacokinetic profile of 14C-labeled clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),[mg-eqv] / [l],3.9,241798,DB00758,Clopidogrel
,10440420,time,A Cmax of 3.9 mg-Eqv/L was reached after a median time of 1 hour (Tmax).,Pharmacokinetic profile of 14C-labeled clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,1,241799,DB00758,Clopidogrel
,10440420,Tmax,A Cmax of 3.9 mg-Eqv/L was reached after a median time of 1 hour (Tmax).,Pharmacokinetic profile of 14C-labeled clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,1,241800,DB00758,Clopidogrel
,10440420,"plasma elimination half-life, t1/2","The plasma elimination half-life, t1/2, ranged from 336 hours to 672 hours in Period I and from 275 to 433 hours in Period II.",Pharmacokinetic profile of 14C-labeled clopidogrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,336,241801,DB00758,Clopidogrel
,10440420,"plasma elimination half-life, t1/2","The plasma elimination half-life, t1/2, ranged from 336 hours to 672 hours in Period I and from 275 to 433 hours in Period II.",Pharmacokinetic profile of 14C-labeled clopidogrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,672,241802,DB00758,Clopidogrel
,10440420,"plasma elimination half-life, t1/2","The plasma elimination half-life, t1/2, ranged from 336 hours to 672 hours in Period I and from 275 to 433 hours in Period II.",Pharmacokinetic profile of 14C-labeled clopidogrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,275 to 433,241803,DB00758,Clopidogrel
,10440420,time to last measurable radioactivity,The radiocarbon excretion over 10 to 12 hours post-dose (time to last measurable radioactivity) in expired air represented 0.31 to 0.35% of the administered dose.,Pharmacokinetic profile of 14C-labeled clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,10 to 12,241804,DB00758,Clopidogrel
,10440420,total excretion,Mean total excretion of radioactivity was 92% of the dose during Period I and 93% during Period II.,Pharmacokinetic profile of 14C-labeled clopidogrel. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),%,92,241805,DB00758,Clopidogrel
,10440420,total excretion,Mean total excretion of radioactivity was 92% of the dose during Period I and 93% during Period II.,Pharmacokinetic profile of 14C-labeled clopidogrel. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),%,93,241806,DB00758,Clopidogrel
,25222745,m/z transitions,"Quantification was performed using multiple reaction monitoring in positive mode with m/z transitions of 333.1-261.0, 333.1-261.0, 347.0-261.0 and 322.2-184.1 for 67M-1, 67M-2, 67M-4 and clopidogrel (Internal Standard), respectively.","An HPLC-MS/MS method for simultaneous determination of the active metabolites of febuxostat (67M-1, 67M-2 and 67M-4) in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25222745/),,333,242092,DB00758,Clopidogrel
,25222745,m/z transitions,"Quantification was performed using multiple reaction monitoring in positive mode with m/z transitions of 333.1-261.0, 333.1-261.0, 347.0-261.0 and 322.2-184.1 for 67M-1, 67M-2, 67M-4 and clopidogrel (Internal Standard), respectively.","An HPLC-MS/MS method for simultaneous determination of the active metabolites of febuxostat (67M-1, 67M-2 and 67M-4) in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25222745/),,333.,242093,DB00758,Clopidogrel
,25222745,m/z transitions,"Quantification was performed using multiple reaction monitoring in positive mode with m/z transitions of 333.1-261.0, 333.1-261.0, 347.0-261.0 and 322.2-184.1 for 67M-1, 67M-2, 67M-4 and clopidogrel (Internal Standard), respectively.","An HPLC-MS/MS method for simultaneous determination of the active metabolites of febuxostat (67M-1, 67M-2 and 67M-4) in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25222745/),,34,242094,DB00758,Clopidogrel
,25222745,m/z transitions,"Quantification was performed using multiple reaction monitoring in positive mode with m/z transitions of 333.1-261.0, 333.1-261.0, 347.0-261.0 and 322.2-184.1 for 67M-1, 67M-2, 67M-4 and clopidogrel (Internal Standard), respectively.","An HPLC-MS/MS method for simultaneous determination of the active metabolites of febuxostat (67M-1, 67M-2 and 67M-4) in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25222745/),,322,242095,DB00758,Clopidogrel
,23192851,transformation efficiency,"The transformation efficiency of vicagrel to 2-oxo-clopidogrel was 94%, but only 13% of clopidogrel was converted to 2-oxo-clopidogrel.","Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192851/),%,94,245986,DB00758,Clopidogrel
,22706585,maximal,The maximal ADP-induced platelet aggregation (2 μmol/L) was decreased in EMs compared with PMs.,Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706585/),[μM] / [l],2,246160,DB00758,Clopidogrel
,27260150,half-life,"Clopidogrel increased the area under the plasma concentration-time curve (AUC0-∞) of pioglitazone 2.1-fold [P < 0.001, 90% confidence interval (CI) 1.8-2.6] and prolonged its half-life from 6.7 to 11 hours (P = 0.002).",Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27260150/),h,6.7,249674,DB00758,Clopidogrel
,27260150,half-life,"Clopidogrel increased the area under the plasma concentration-time curve (AUC0-∞) of pioglitazone 2.1-fold [P < 0.001, 90% confidence interval (CI) 1.8-2.6] and prolonged its half-life from 6.7 to 11 hours (P = 0.002).",Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27260150/),h,11,249675,DB00758,Clopidogrel
,22515556,maximum (peak) plasma concentration (C(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],733,250416,DB00758,Clopidogrel
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.0,250417,DB00758,Clopidogrel
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],210,250418,DB00758,Clopidogrel
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.1,250419,DB00758,Clopidogrel
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],4130,250420,DB00758,Clopidogrel
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],1325,250421,DB00758,Clopidogrel
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],305,250422,DB00758,Clopidogrel
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],121,250423,DB00758,Clopidogrel
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],724,250424,DB00758,Clopidogrel
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],764,250425,DB00758,Clopidogrel
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3983,250426,DB00758,Clopidogrel
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3986,250427,DB00758,Clopidogrel
,18030066,area under the concentration-time curve (AUC0-tlast),Active metabolite area under the concentration-time curve (AUC0-tlast) after prasugrel 60-mg (594 ng.hr/mL) was 2.2 times that after clopidogrel 600-mg.,Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030066/),[h·ng] / [ml],594,252650,DB00758,Clopidogrel
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,70.42,254540,DB00758,Clopidogrel
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,69.45,254541,DB00758,Clopidogrel
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,65.58,254542,DB00758,Clopidogrel
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,56.6,254543,DB00758,Clopidogrel
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],3.6,254544,DB00758,Clopidogrel
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],6.9,254545,DB00758,Clopidogrel
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],12.4,254546,DB00758,Clopidogrel
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],34.0,254547,DB00758,Clopidogrel
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,706,265349,DB00758,Clopidogrel
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,221,265350,DB00758,Clopidogrel
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,283,265351,DB00758,Clopidogrel
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,21,267874,DB00758,Clopidogrel
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,1.,267875,DB00758,Clopidogrel
,16637000,linear dynamic,The assay exhibited a linear dynamic range of 5-6000 pg/mL for clopidogrel in human plasma.,Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637000/),[pg] / [ml],5-6000,268599,DB00758,Clopidogrel
,16637000,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637000/),min,2.5,268600,DB00758,Clopidogrel
,16423907,impedance,Mean (SD) impedance of the healthy cohort was 12.2 (2.2) Omega.,Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,12.2,268825,DB00758,Clopidogrel
<,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268826,DB00758,Clopidogrel
>,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268827,DB00758,Clopidogrel
,25256597,IC50,The IC50 value was 2.1 µM.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),μM,2.1,268846,DB00758,Clopidogrel
,25256597,AUC0-∞,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],0.9,268847,DB00758,Clopidogrel
,25256597,AUC0-∞,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],1.7,268848,DB00758,Clopidogrel
,25256597,Cmax,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],0.4,268849,DB00758,Clopidogrel
,25256597,Cmax,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],0.9,268850,DB00758,Clopidogrel
,25256597,AUC0-∞,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],18.2,268851,DB00758,Clopidogrel
,25256597,AUC0-∞,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],11.4,268852,DB00758,Clopidogrel
,25256597,Cmax,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],8.2,268853,DB00758,Clopidogrel
,25256597,Cmax,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],4.3,268854,DB00758,Clopidogrel
,24127209,maximum plasma concentration [C max],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[ng] / [ml],5.29,269288,DB00758,Clopidogrel
,24127209,maximum plasma concentration [C max],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[ng] / [ml],7.13,269289,DB00758,Clopidogrel
,24127209,area under the plasma concentration-time curve from time zero to time t [AUC t ],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[h·ng] / [ml],7.37,269290,DB00758,Clopidogrel
,24127209,area under the plasma concentration-time curve from time zero to time t [AUC t ],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[h·ng] / [ml],11.30,269291,DB00758,Clopidogrel
,24127209,Platelet,Platelet aggregation measured with a Multiplate analyser ranged between 37 and 747 AU·min.,Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),au·min,37 and 747,269292,DB00758,Clopidogrel
,24127209,aggregation,Platelet aggregation measured with a Multiplate analyser ranged between 37 and 747 AU·min.,Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),au·min,37 and 747,269293,DB00758,Clopidogrel
